Astellas seeks to expand reimbursement for prostate cancer drug Xtandi

Korea Biomedical Review

16 May 2023 - Astellas Pharma has set about to rectify the reimbursement track for Xtandi (enzalutamide), its prostate cancer treatment that caused confusion in the clinical field by receiving selective reimbursement for the same indications differently from competitor drugs.

Astellas recently submitted an application for Xtandi’s essential reimbursement to HIRA.

Last August, Xtandi received expanded reimbursement for treating metastatic hormone-sensitive prostate cancer patients combined with androgen deprivation therapy.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Market access , Korea